MBX Biosciences elects directors, ratifies auditor
MBX Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders held on June 4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MBX Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders held on June 4, 2026. Stockholders elected two Class II directors, Patrick J. Heron and Edward T. Mathers, to serve terms ending at the 2029 annual meeting.
As of the April 10, 2026 record date, there were 47,570,485 outstanding shares of common stock. Heron received 35,007,623 votes for and 4,579,129 withheld, while Mathers received 31,983,223 votes for and 7,603,529 withheld, with 4,130,833 broker non-votes for each. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 43,713,693 votes for, 1,946 against and 1,946 abstentions.
8-K Event Classification
Key Figures
Key Terms
emerging growth company regulatory
Class II director financial
record date financial
independent registered public accounting firm financial
broker non-votes financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MBX (MBX) stockholders approve at the 2026 annual meeting?
What were the vote results for MBX director Patrick J. Heron?
How did MBX stockholders vote on director Edward T. Mathers?
Did MBX (MBX) stockholders ratify Ernst & Young LLP as auditor for 2026?
When was MBX’s 2026 annual meeting held and what proposals were considered?
AI-generated analysis. How Rhea-AI works. Not financial advice.